Adrenomedullin vs Cortexin

Adrenomedullin and Cortexin represent fundamentally different classes of research peptides. Adrenomedullin is a single, well-defined 52-amino-acid peptide with potent vasodilatory properties, primarily investigated in cardiovascular and sepsis contexts. In contrast, Cortexin is a multi-component neuropeptide extract from bovine and porcine cerebral cortex, containing a complex mixture of polypeptides, amino acids, and other bioactive molecules. This comparison delineates their mechanisms, evidence bases, and safety profiles, highlighting key distinctions that inform research design.

Adrenomedullin, a 52-amino-acid vasodilatory peptide (molecular weight ~6028 g/mol), was first isolated from human pheochromocytoma tissue. It is widely expressed in the cardiovascular system, lungs, kidneys, and adrenal glands, exerting potent vasodilatory, natriuretic, and cardioprotective effects. Research indicates that its mid-regional fragment, MR-proADM, serves as a robust prognostic biomarker in sepsis and acute heart failure, with studies demonstrating strong predictive value for mortality. Despite its promising biomarker utility, Adrenomedullin itself has no approved therapeutic use, and clinical investigations remain limited to experimental settings.

Cortexin is a complex neuropeptide preparation derived from the cerebral cortex of cattle and pigs, containing a mixture of low-molecular-weight polypeptides (up to 10 kDa), amino acids, vitamins, and trace minerals. Unlike single-sequence peptides, it is a multi-component extract. Registered as a pharmaceutical in Russia and CIS countries since 1999 for neurological conditions including ischemic stroke, TBI, and cognitive impairment. Not approved by FDA, EMA, or other Western regulatory agencies. Research demonstrates multi-target neuroprotective activity including caspase-8 inhibition, antioxidant defense, and BDNF modulation.

Key claims: Neuroprotection in ischemic stroke; Inhibits brain caspase-8 (anti-apoptotic); Antioxidant effects in cerebrovascular insufficiency.

Adrenomedullin and Cortexin target distinct research domains with minimal overlap. Adrenomedullin is primarily investigated in cardiovascular and critical care contexts, including sepsis prognostication, heart failure biomarker development, and vasodilation studies. Cortexin, conversely, is focused on neurological research, particularly neuroprotection, stroke recovery, and cognitive support. These divergent applications reflect their unique mechanisms and evidence bases, with Adrenomedullin emphasizing systemic hemodynamic regulation and Cortexin targeting central nervous system repair.

Adrenomedullin lacks human safety data from controlled therapeutic trials. Experimental intravenous infusion in healthy volunteers has been associated with hypotension and reflex tachycardia, suggesting a theoretical risk of excessive vasodilation and hemodynamic instability. In contrast, Cortexin has a substantial clinical safety record from pharmaceutical use in Russia and CIS countries since 1999. The most common adverse effect is injection site reactions (pain, redness, swelling) from intramuscular administration, with rare allergic or hypersensitivity reactions reported, consistent with its animal-derived protein composition.